Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
NovartisNovartis(US:NVS) WSJ·2026-03-20 06:33

Core Insights - Novartis is evaluating SNV4818 in early and mid-stage studies for breast cancer and other advanced solid tumors [1] Company Overview - The focus of Novartis on SNV4818 indicates a strategic investment in oncology research, particularly targeting breast cancer and advanced solid tumors [1]